SCHEMBL4724848

SCHEMBL4724848

CCOc1ccc(N2CCCC2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.69
ALDH1A1 P00352 4/20 0.69
KMT2A Q03164 4/20 0.69
GAA P10253 3/20 0.69
MEN1 O00255 3/20 0.69
ALOX15 P16050 2/20 0.69
KDM4E B2RXH2 2/20 0.69
L3MBTL1 Q9Y468 2/20 0.69
APP P05067 1/20 0.69
ALOX12 P18054 1/20 0.69
MAPK1 P28482 1/20 0.69
SNCA P37840 1/20 0.69
TDP1 Q9NUW8 1/20 0.69
HSD17B10 Q99714 1/20 0.64
NPC1 O15118 2/20 0.61
RAB9A P51151 2/20 0.61
TP53 P04637 1/20 0.61
BACE1 P56817 1/20 0.61
SMN1; SMN2 Q16637 1/20 0.61
KCNH2 Q12809 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4720351 0.98 MAPT (0.68) MAPTALDH1A1KMT2AGAAMEN1
SCHEMBL27363642 0.92 MAPT (0.65) MAPTALDH1A1KMT2AGAAMEN1
SCHEMBL10769299 0.90 MAPT (0.59) MAPTALDH1A1KMT2AGAAMEN1
SCHEMBL9670983 0.87 ALDH1A1 (0.64) MAPTALDH1A1KMT2AGAAMEN1
SCHEMBL18773677 0.86 KMT2A (0.60) MAPTALDH1A1KMT2AGAAMEN1
SCHEMBL10473982 0.86 ALDH1A1 (0.62) MAPTALDH1A1KMT2AGAAMEN1
SCHEMBL10473983 0.86 ALDH1A1 (0.62) MAPTALDH1A1KMT2AGAAMEN1
Phenetole SCHEMBL28303013 0.85 MAPT (0.55) MAPTALDH1A1KMT2AGAAMEN1
SCHEMBL5238114 0.85 ADRB1 (0.58) MAPTALDH1A1KMT2AGAAMEN1
SCHEMBL8363117 0.85 KMT2A (0.66) MAPTALDH1A1KMT2AGAAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 MAPT 4361/4885ALDH1A1 622/4885KMT2A 3345/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.